S&CO Inc. Acquires 635 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

S&CO Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 38,961 shares of the medical research company's stock after purchasing an additional 635 shares during the quarter. Thermo Fisher Scientific accounts for about 1.4% of S&CO Inc.'s holdings, making the stock its 17th biggest holding. S&CO Inc.'s holdings in Thermo Fisher Scientific were worth $20,268,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Riverbend Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $312,000. Daiwa Securities Group Inc. increased its stake in shares of Thermo Fisher Scientific by 6.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 60,428 shares of the medical research company's stock worth $31,436,000 after buying an additional 3,700 shares during the period. Moran Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. Moran Wealth Management LLC now owns 1,089 shares of the medical research company's stock worth $567,000 after buying an additional 26 shares during the period. Isthmus Partners LLC increased its stake in shares of Thermo Fisher Scientific by 152.3% in the fourth quarter. Isthmus Partners LLC now owns 1,438 shares of the medical research company's stock worth $748,000 after buying an additional 868 shares during the period. Finally, Argentarii LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $975,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the transaction, the chief executive officer now owns 115,174 shares of the company's stock, valued at approximately $59,506,950.58. The trade was a 7.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 23,900 shares of company stock worth $13,106,062. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $1.06 on Wednesday, hitting $515.26. 886,654 shares of the company's stock were exchanged, compared to its average volume of 1,528,330. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $194.39 billion, a PE ratio of 31.09, a PEG ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The company has a 50-day simple moving average of $549.14 and a 200-day simple moving average of $560.79.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its board has approved a stock buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's leadership believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.33%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date is Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.41%.

Analyst Ratings Changes

Several research analysts have commented on TMO shares. Wells Fargo & Company upped their price objective on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. Bank of America decreased their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a research report on Friday, December 13th. UBS Group increased their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Scotiabank increased their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Finally, StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.